Stephan Rosenkranz, MD, is an interventional cardiologist, and serves as the Head of the Pulmonary Hypertension (PH) Center at the University of Cologne, Germany, and leads the Cologne Cardiovascular Research Center (CCRC). He graduated from Justus Liebig University Giessen, Germany, before becoming a physician and research fellow at the University of Cologne. He also undertook a post-doctoral fellowship at Harvard Medical School, USA, before returning to Cologne. He is currently the Chair of the Working Group “Pulmonary Circulation and Right Ventricular Function” of the European Society of Cardiology. His research interests include cardiopulmonary interaction and right ventricular function in left heart disease, and signal transduction and biological importance of tyrosine kinases and stress signalling in cardiovascular disease. He has been involved in numerous clinical trials in the fields of atherosclerosis, heart failure and PH, and received numerous scientific awards.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease